OWINGS MILLS, Md., July 31 /PRNewswire-FirstCall/ -- Medifast, Inc.
(NYSE: MED) today announced that a recent study published in 'The Journal of
Eating and Weight Disorders' shows that individuals taking appetite
suppressant medications can expect double the weight loss when they combine
their drug therapy with a medical protocol using Medifast Meal Replacement
Supplements.
The 52-week study, conducted by researchers at the University of
Missouri-Kansas City School of Medicine and Baylor College of Medicine shows
that participants who consistently used Medifast Meal Replacements along with
pharmacotherapy lost an average of 14% of their body weight in one year. This
amount of weight loss is approximately double what is seen in university
studies of obesity medications alone over the same time frame. In the study,
more than 80% of the participants lost at least 5% of their body weight, which
is more than double that found for other structured commercial weight loss
programs.
'The results of studies featuring Medifast Meal Replacements are superior
to those typically observed for other obesity interventions including weight
loss medications and other commercial weight loss plans,' says Lisa M. Davis,
Ph.D., PA-C, C.N.S., L.D.N., Director of Research and Development, Medifast,
Inc. 'This suggests that comprehensive weight control programs featuring
Medifast provide a unique solution for weight control.'
While the Company does not advocate the use of weight loss drugs, Medifast
does recognize that diet pills are part of the weight loss landscape now and
are likely to remain so in the future. Medifast is a proven weight control
program in and of itself, and has now been shown to double the results of
comprehensive weight control programs employing appetite suppressant
medications.
Medifast will continually participate in studies in the future, which will
add even more credibility to the Brand and its Programs. For more than 25
years Medifast has been prescribed by practitioners as a safe and effective
program that has been clinically proven to yield significant weight loss of
2-5 pounds per week.
Since 1980, 15,000 physicians from across the country have trusted
Medifast to provide their patients with the highest quality, nutritious weight
loss and disease management solutions.
MED-G
About Medifast:
Medifast (NYSE: MED) is the leading easy-to-use, clinically proven
portion-controlled weight loss program. Medifast has been recommended by
15,000 physicians and used by over one million customers. Medifast is
committed to enriching lives by providing innovative choices for lasting
health. Medifast programs have been proven effective through studies by major
university teaching hospitals. The company sells its products and programs via
four unique distribution channels: 1) the web and national call centers, 2)
the Take Shape For Life direct-selling division, a network of health coaches,
3) medically supervised Medifast Weight Control Centers, and 4) national
network of physicians. Medifast was founded in 1980 and is located in Owings
Mills, Maryland. For more information, log onto http://www.choosemedifast.com.
SOURCE Medifast, Inc.
